Follow the enGene Therapeutics Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in Canada. Shares trade on CA CA, under the authority of SEDI. Market capitalisation: €123.9m. The latest transaction was filed on 24 July 2026 (00 - Opening Balance-Initial SEDI Report). Among the most active insiders: Richton, Kathleen Patricia. All data is free.
18
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate enGene Therapeutics Inc. Hold (neutral), based on 7 analysts. Average price target: US$3.29.
19Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
enGene Therapeutics Inc. is a biopharmaceutical company focused on developing gene therapies for serious diseases. It is listed on the Toronto Stock Exchange under the symbol XTSE.